News
HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.
1h
Stocktwits on MSNNovo Nordisk’s Weight-Loss Drug Wegovy Launched In Thailand, Marks Entry Into Southeast AsiaNovo Nordisk (NVO) has launched its weight-loss drug Wegovy in Thailand, Reuters reported on Monday, citing an executive of ...
Todd Engel claims Ozempic caused his blindness. Lawsuit says Novo Nordisk failed to warn of rare vision risks.
Their own mini-boom of recent years has been largely fueled by one firm, Ozempic maker Novo Nordisk A/S, whose diabetes and ...
Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...
Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...
A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...
Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.
Ozempic and similar weight loss drugs are currently at the center of multidistrict litigation over claims that the drugs ...
The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...
2d
Stocktwits on MSNNovo Nordisk Wins Another Legal Battle Against Compounding Of Wegovy, Ozempic: Retail’s BullishNovo Nordisk (NVO) announced on Friday that it has secured a legal victory against compounders selling unauthorized versions ...
A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results